6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
The DOI matches its Crossref record; 117 of the 118 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc21-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc21-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These findings have informed clinical practice guidelines and policy, which now recommend that SMBG not be used routinely in this group (21–26).”
In the citing paper
“While the drug manufacturer is currently offering a savings card program for some patients for whom pricing is a barrier, payor coverage for tirzepatide will likely be a barrier to patient use, especially before tirzepatide has been officially recognized as a standard of care in professional guidelines. 2”
From Tirzepatide: Clinical review of the twincretin injectable (2023) · cites this paper as [2]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 2×
“33% with metformin as initial pharmacotherapy) and in all-cause mortality (13% and 27%, respectively) (33).”
BackgroundIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
Research works printed but not linked: 1
- Dicembrini, Impact of technology on glycemic control in type 2 diabetes: a meta-analysis of randomized trials on continuous glucose monitoring and continuous subcutaneous insulin infusion, Diabetes Obes Metab
Cited by
Items 501–600 of 846
Suzuki, R., Shoji, S., Yoshinaga, Y., Kosakai, Y., & Shintani‐Tachi, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16188 · Cited by 3
“4,5 The progression of T2DM causes pancreatic β -cell insufficiency and insulin resistance, resulting in chronic hyperglycaemia.”
Farnham, C., Liu, I. Z., Agarwal, A. R., Parel, P. M., Quan, T., Durand, W. M., Raad, M., & Jain, A. (2025) · Global Spine Journal · doi:10.1177/21925682251315098 · Cited by 3
“32 32-34 Therefore, due to the risks of both high and low levels of serum glucose, careful management of peri-operative serum glucose levels is of great importance.”
Dera, A. A., Alghamdi, A. A., Shahrani, M. M. A., Al‐Gahtani, R. M., Alghamdi, B., Zaman, G. S., Rasheed, M. A., Al‐Shehri, H., Al‐qhtani, L., Ali, S. P., et al. (2025) · Animal Models and Experimental Medicine · doi:10.1002/ame2.70023 · Cited by 3
Liu, L., You, Q., Yu, W., Lett, A. M., Wu, Y., Zeng, J., Fan, M., Chen, B., Fu, W., & Xu, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1554798 · Cited by 3
Lilly, A. N., King, C. A., & Ortiz, J. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70090 · Cited by 4
Rehan, I., Rehman, M. U., Aamir, M., & Islam, S. (2025) · Microchemical Journal · doi:10.1016/j.microc.2025.114980 · Cited by 3
Thilakarathna, M., Appuhami, K., Darshana, N., & Perera, J. A. (2025) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-025-05077-5 · Cited by 3
Krishnamoorthy, S., Renu, K., & Veeraraghavan, V. P. (2026) · Cardiovascular Toxicology · doi:10.1007/s12012-026-10097-9 · Cited by 3
“It has ben - eficial effects and also side effects [ 58].”
Workplace Experiences of Young Adults With Type 1 Diabetes: A Social-Ecological Perspective
Saylor, J. L., Yorgason, J. B., Ness, M. M., Millett, M. A., Jackson, A., & Sabino, A. F. (2021) · Emerging Adulthood · doi:10.1177/21676968211020234 · Cited by 7
Evaluation of a New Clinical Tool to Enhance Clinical Care of Control-IQ Users
Messer, L. H., Berget, C., Centi, S. M., McNair, B. K., & Forlenza, G. P. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221081890 · Cited by 3
Yu, Z., Chen, C., Yu, T., Ye, Y., Zheng, X., Zhan, S., Zeng, S., Zou, X., & Chang, Y. (2023) · European Spine Journal · doi:10.1007/s00586-023-07605-8 · Cited by 3
Impact of anemia on HbAC level in type 2 diabetes mellitus patients
Gulavani, G. A., Panchbudhe, S. A., Gawade, S. H., & Mujawar, F. B. (2023) · International Journal of Clinical Biochemistry and Research · doi:10.18231/j.ijcbr.2023.020 · Cited by 3
Panagiotidis, P., Kalokairinou, A., Tzavara, C. K., Michailidou, A., & Velonaki, V. S. (2024) · Cureus · doi:10.7759/cureus.55691 · Cited by 8
Park, C., Larsen, B. A., Mogos, M. F., Muchira, J. M., Dietrich, M. S., LaNoue, M. D., Jean, J., Norfleet, J., Doyle, A., Ahn, S., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302582 · Cited by 3
Preventing Infections in Reverse Shoulder Arthroplasty
Saad, M. A., Moverman, M. A., Silva, A. Z. D., & Chalmers, P. N. (2024) · Current Reviews in Musculoskeletal Medicine · doi:10.1007/s12178-024-09918-7 · Cited by 3
“Pre operatively, an A1C cutoff of 8% can be used or glucose targets of 80–130 mg/dl pre-prandial and 180 mg/ dl 1–2 h post-prandial [31, 32].”
Magris, R., Monte, A., Nardello, F., Trinchi, M., Vigolo, N., Negri, C., Moghetti, P., & Zamparo, P. (2024) · European Journal of Applied Physiology · doi:10.1007/s00421-024-05596-y · Cited by 4
“Regarding glycaemic control, the American Diabetes Association (American Diabetes Association 2021) indicates a threshold of 53 mmol/molHb for a substantially increased risk of adverse effects of diabetes.”
Hadid, S. A., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000940 · Cited by 3
Amirthalingam, P., Alatawi, O. S., Hamdan, A. M., Aljabri, A. M., Alqifari, S. F., Alshareef, H. M., Hakami, F. A. M., Albalawi, N. S., Albrahimi, H. M. A., Alanazi, S., et al. (2025) · Patient Preference and Adherence · doi:10.2147/ppa.s534534 · Cited by 4
Sherrill, C. H., Houpt, C. T., Dixon, E. M., & Richter, S. J. (2021) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1427 · Cited by 4
Clinical Use and Limitation of Hemoglobin A1c Examination
Suastika, K. (2021) · Clinical Diabetology · doi:10.5603/dk.a2021.0045 · Cited by 5
Seroprotection Status of Hepatitis B Vaccine in Children with Type 1 Diabetes Mellitus
Elsharkawy, D., El-khaleegy, H., Mohamed, S. A., & Mohamed, G. A. (2021) · International Journal of Medical Arts · doi:10.21608/ijma.2021.81707.1331 · Cited by 3
Cardiovascular Disease in Patients with Diabetes: A Comparison of Professional Society Guidelines
Sarkar, S., Salazar, I. M. C., Tibuakuu, M., & Blumenthal, R. S. (2021) · Current Diabetes Reviews · doi:10.2174/1573399817666210820105514 · Cited by 3
Lipski, J., Duda‐Sobczak, A., Napierała, M., Florek, E., Zozulińska‐Ziółkiewicz, D., & Wyganowska‐Świątkowska, M. (2021) · Antioxidants · doi:10.3390/antiox10111732 · Cited by 4
Pasqualetti, S., Carnevale, A., Dolci, A., & Panteghini, M. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-1249 · Cited by 5
Varadhan, L., Saravanan, P., Ali, S. N., Hanif, W., & Patel, V. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-021-01105-7 · Cited by 3
A view at postbariatric hypoglycemia by endocrinologist
Kim, E. I., Ershova, E. V., Mazurina, N. V., & Komshilova, K. A. (2022) · Obesity and metabolism · doi:10.14341/omet12785 · Cited by 3
Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes: Hypothetical Case Studies
Harris, S. B., Parente, E. B., & Karalliedde, J. J. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01247-7 · Cited by 3
Optimal Type 2 Diabetes Mellitus Management and Active Ageing
Calabrese, A. M., Calsolaro, V., Rogani, S., Okoye, C., Caraccio, N., & Monzani, F. (2021) · Endocrines · doi:10.3390/endocrines2040047 · Cited by 4
Mitchell, B. D., Rentz, A. M., Kummer, S., Yan, Y., Heidenreich, S., Krucien, N., Artime, E., Osumili, B., Rubio, M., & Gelhorn, H. L. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221095882 · Cited by 3
“3,4 .”
Insulinoma after sleeve gastrectomy: A case report
Lobaton-Ginsberg, M., Sotelo-González, P., Ramírez‐Rentería, C., Juárez-Aguilar, F. G., & Ferreira‐Hermosillo, A. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i18.6227 · Cited by 3
Katz, A. J., Chen, R. C., Usinger, D., Danus, S. M., & Zullig, L. L. (2022) · Journal of Cancer Survivorship · doi:10.1007/s11764-022-01229-5 · Cited by 3
Cutruzzolà, A., Parise, M., Fiorentino, R., Romano, A., Molinaro, V., Gnasso, A., Molfetta, S. D., & Irace, C. (2022) · Nutrients · doi:10.3390/nu14163316 · Cited by 4
Variation of glucose time in range in type 1 diabetes
Hansen, K. W., & Bibby, B. M. (2022) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.379 · Cited by 2
Performance Evaluation of the DxC 700 AU Chemistry Analyzer in Hemoglobin A1c Measurement
Choi, Y. J., Kang, H., Cho, C.-I., Rim, J. H., Lee, S., & Lim, J. (2022) · Annals of Laboratory Medicine · doi:10.3343/alm.2023.43.2.167 · Cited by 4
Nazu, N. A., Wikström, K., Lamidi, M., Lindström, J., Tirkkonen, H., Rautiainen, P., & Laatikainen, T. K. (2022) · BMC Family Practice · doi:10.1186/s12875-022-01889-3 · Cited by 3
Rivera, A. S., Plank, M., Davis, A., Feinstein, M. J., Rusie, L. K., & Beach, L. B. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-002990 · Cited by 4
Risk factors for severe rhino-orbital mucormycosis during its epidemic post-COVID-19 pandemic
Beri, N., Das, G., Singh, A., Sahu, P. K., Bisht, T., & Sharma, I. (2022) · Indian Journal of Public Health · doi:10.4103/ijph.ijph_714_22 · Cited by 2
Perfil bioquímico de usuários diabéticos e hipertensos vinculados a Atenção Primária à Saúde
de Melo, G. R. N., Nogueira, J. C. D. C., Kono, E. M., de Souza, J., Takanashi, S. Y. L., & Gouvêa-e-Silva, L. F. (2023) · Medicina (Ribeirão Preto) · doi:10.11606/issn.2176-7262.rmrp.2023.202897 · Cited by 6
Martínez, I. M. P., Pastor, A. M., García, J. J. G., Barquilla-García, A., Martín, V., Pérez, R. M., & Divisón, J. A. (2023) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2023.07.001 · Cited by 3
Williams, K. J., Bashan, E., Kruse, C., Sritharan, S. S., & Hodish, I. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15280 · Cited by 3
Kong, Y. W., Yuan, C. Y., Kiburg, K., Brown, K., Trawley, S. L., Partovi, A., ROEM, K. L., Harrison, N., Fourlanos, S., Ekinci, E. I., et al. (2023) · Pilot and Feasibility Studies · doi:10.1186/s40814-023-01400-4 · Cited by 3
“Hypoglycaemic events, defined as an event where typical symptoms of hypoglycaemia are accompanied by a finger-prick blood glucose (BG) measurement of less than 3.9mmol/L [16], will be recorded in real-time using the KeyLead Health ™ (Melbourne, Australia) mobile application (Table 4).”
BackgroundMethodParimi, V., Elsner, A. E., Gast, T. J., Chen, Z., Baskaran, K., Alhamami, M. A., Litvin, T. V., Ozawa, G. Y., & Cuadros, J. A. (2024) · Optometry and Vision Science · doi:10.1097/opx.0000000000002096 · Cited by 3
Yang, Q., Jiang, M., Li, C., Luo, S., Crowley, M. J., & Shaw, R. J. (2024) · BMC Medical Research Methodology · doi:10.1186/s12874-024-02193-7 · Cited by 5
“Although Hemoglobin A1c (HbA1c) is the main health indicator for type 2 diabetes mellitus patients, patients usually need to visit clinics and have HbA1c checked in a lab every 3–6 months [36].”
BackgroundOptimizing Blood Glucose Control through Reward Shaping in Reinforcement Learning
Rad, F. S., & Li, J. (2023) · IEEE International Conference on e-Health Networking, Applications and Services (Healthcom) · doi:10.1109/healthcom56612.2023.10472341 · Cited by 5
“Among the many critical facets of diabetes management, achieving effective blood glucose control stands out as a pivotal objective [1].”
BackgroundSvensson, A., Dahlin, L. B., Rydberg, M., Perez, R., & Zimmerman, M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302219 · Cited by 3
Wesche, J., Bakken, T., Vetrhus, M., Hufthammer, K. O., Nyroenning, L. A., Fagertun, H. E., Saethre, I., Wold, B. H., Lyng, C. S., Pettersen, E. M., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02421-w · Cited by 4
“Also, the preoperative mean HbA 1c in the DM patients were 52 mmol/mol (6.9%), which is in accordance with general treatment goals according to the DM guidelines [39–41].”
ResultInfluentialLi, Y., Zou, K., Wang, Y., Zhang, Y., Zhong, J., Wu, Z., Tang, F., Lu, P., Liu, X., & Deng, L. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2517403 · Cited by 3
“Subgroup analyses were conducted to bolster the robustness of our findings.”
Pulido‐Perez, P., Torres‐Rasgado, E., Pérez-Fuentes, R., Rosales‐Encina, J. L., Rodríguez‐Antolín, J., & Romero, J. R. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107974 · Cited by 3
Gökalp, F., Koraş, Ö., Gürsoy, D., Şığva, H., Porgalı, S. B., Tamkaç, N., Kulak, B., Uçurmak, F., & Görür, S. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14923 · Cited by 3
La variabilité glycémique : un facteur de risque singulier à conjuguer au pluriel
Monnier, L., Colette, C., Bonnet, F., & Owens, D. R. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.11.003 · Cited by 3
Cost of Severe Hypoglycemia and Budget Impact with Nasal Glucagon in Patients with Diabetes in Spain
Osumili, B., Artime, E., Mitchell, B. D., Santos, M. R., Díaz‐Cerezo, S., Giménez, M., Spaepen, E., Sharland, H., & Valentine, W. J. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01238-8 · Cited by 3
López, L. V., del Prado, P. S. C., Colin-Ramírez, E., Muñoz-Torres, A. V., & la Peña, J. E.-D. (2022) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2022.03.002 · Cited by 5
Stuckey, H. L., Desai, U. S., Mitchell, B. D., & Pearson, T. L. (2023) · Diabetic Medicine · doi:10.1111/dme.15084 · Cited by 3
A glikációs index lehetséges magyarázata a hemoglobinglikáció biokinetikus modellje alapján
Rácz, O., Barkai, L., Eigner, G., Kovács, L., Bicsák, M., Muriová, K., & Dombrovský, P. (2021) · Orvosi Hetilap · doi:10.1556/650.2021.32203 · Cited by 3
Saboo, B., Erande, S. G., & Unnikrishnan, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102394 · Cited by 3
Scharbarg, E., Greck, J., Carpentier, É. L., Chaillous, L., & Moog, C. H. (2022) · Scientific Reports · doi:10.1038/s41598-022-11772-x · Cited by 4
Cortez, B. N., Pan, H., & Aguayo‐Mazzucato, C. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.14.507908 · Cited by 3
The benefits of terpenoids as functional foods for the managementof type 2 diabetes mellitus
Martirosyan, D. M., & Christopher, S. (2024) · Bioactive Compounds in Health and Disease · doi:10.31989/bchd.v7i7.1426 · Cited by 3
“In 2022, Diabetes was America's seventh leading cause of death [2].”
BackgroundDavidson, M. B. (2022) · Diabetes Spectrum · doi:10.2337/ds21-0001 · Cited by 2
Ruiz‐García, A., Pallarés‐Carratalá, V., Serrano-Cumplido, A., Escobar-Cervantes, C., Barquilla-García, A., Divisón, J. A., Turégano-Yedro, M., Prieto-Díaz, M. Á., Cinza‐Sanjurjo, S., Alonso-Moreno, F. J., et al. (2022) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2021.12.002 · Cited by 2
Inoue, S., Tsuruda, S., Tsuruta, A., Kishikawa, M., Yamazaki, K., Ibaraki, K., Yamashiro, Y., & Koga, M. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.10.015 · Cited by 2
Akulova, M., Nesterova, A., Isaacs, D. M., Molodkin, E., & Ushakov, M. (2023) · Medical Research Archives · doi:10.18103/mra.v11i7.1.4047 · Cited by 2
The Urgent Need to Define HbA1C Cutoffs in Hand Surgery
Griffin, M., & Curtin, C. M. (2024) · Hand · doi:10.1177/15589447241233358 · Cited by 2
Lee, H. J., Bae, K., Yoon, C. K., Park, U. C., Park, K. H., & Lee, E. K. (2024) · Scientific Reports · doi:10.1038/s41598-024-55078-6 · Cited by 2
dos Santos, R. R., & Costa, J. D. P. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n3-405 · Cited by 2
Post-Ischemic Stroke Cardiovascular Risk Prevention and Management
Guo, Y., Pan, D., Wan, H., & Yang, J. (2024) · Healthcare · doi:10.3390/healthcare12141415 · Cited by 5
“A target of HbA1c control of less than 7% is considered reasonable [92,98].”
BackgroundÖmür, S. E., Koyun, E., Cabri, G., & Zorlu, Ç. (2024) · Biomarkers in Medicine · doi:10.1080/17520363.2024.2380248 · Cited by 2
A CGM-Based model for predicting hypoglycemia in type 2 diabetes patients with TIR in target
Lu, J., Chen, D., Lin, B., Liu, Z., Yang, Y., He, L., Yan, J., Yang, D., & Xu, W. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01713-9 · Cited by 5
“Since 2020, Time in range (TIR) has been recommended as a key metric for assessing glycemic management, representing the percentage of time during which an individual’s blood glucose remains within a target range of 3.9–10 mmol/L [13, 14].”
InfluentialCarcone, A. I., Baskar, D., Mahmood, A., MacDonell, K. K., Eggly, S. S., Ghosh, S., Buggs‐Saxton, C., Ondersma, S. J., & Ellis, D. A. (2025) · JMIR Formative Research · doi:10.2196/75623 · Cited by 3
“Emerging adults have the worst glycemic health indicators of any age group [11], with hemoglobin A 1c (HbA 1c ) levels averaging from 8.4% to 9.3% [5,9] (levels <7% are recommended [12]); 83% fail to meet glycemic recommendations [9].”
InfluentialLiu, Z., & Huang, W. (2025) · Journal of International Medical Research · doi:10.1177/03000605251390098 · Cited by 2
Use of large scale EHR data to evaluate A1c utilization among sickle cell disease patients
Sivasankar, S., Cheng, A., Lubin, I. M., Lankachandra, K. M., & Hoffman, M. A. (2021) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-021-01632-5 · Cited by 4
Individualización del tratamiento de la diabetes mellitus tipo 2
Llavero-Valero, M., Ugalde, B., Huguet, I., & Triviño, V. (2021) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2021.12.003 · Cited by 6
Altun, Ö., & Kalyon, S. (2022) · Meandros Medical And Dental Journal · doi:10.4274/meandros.galenos.2021.27132 · Cited by 4
Hoog, M. M., Smith, J. L., Yu, M. B., Peleshok, J. C., Mody, R., & Grabner, M. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.04.005 · Cited by 2
Effectiveness of Student-Led Interventions on Improving Diabetes Outcomes: A Systematic Review
Nickelson, J., McFadden, N. T., Johnson, P. T., & Boucher, A. (2022) · American Journal of Health Education · doi:10.1080/19325037.2022.2100020 · Cited by 2
Elhag, W., Ansari, W. E., Bashah, M., & Elgenaied, I. (2022) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2022.0043 · Cited by 2
“25,26 To distinguish patients with T2D relapse, in line with others, 11 we first ascertained patients who achieved the criteria for T2D remission within the first year after surgery.”
Lum, K. Y., Oppong, R., & Kigozi, J. (2022) · Asia Pacific Journal of Public Health · doi:10.1177/10105395221122643 · Cited by 2
Nutrition in Pancreatic Cancer
Petzel, M. Q. B., & Ebrus, C. S. (2022) · Springer eBooks · doi:10.1007/978-3-031-05724-3_26 · Cited by 2
Frechtel, G. D., Sauque‐Reyna, L., Choza‐Romero, R., Anguiano, L., Melas‐Melt, L., & Sañudo‐Maury, M. E. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15125 · Cited by 2
Riihimies, R., Kosunen, E., & Koskela, T. (2023) · Journal of Medical Internet Research · doi:10.2196/40560 · Cited by 7
Recomendaciones para la práctica clínica: hipoglucemia en personas con diabetes mellitus
Martín, C. G., Loredo, S. D., Forlino, M., Rodríguez, A., Ré, M., Santos, N. C. G., Dimov, L., Apoloni, S. B., Remón, J., Ávila, P. J., et al. (2022) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v56i2sup.539 · Cited by 4
Ory, M. G., Han, G., Jani, S. N., Zhong, L., Andreyeva, E., Carpenter, K., Towne, S. D., Preston, V. A., & Smith, M. L. (2023) · PLoS ONE · doi:10.1371/journal.pone.0289491 · Cited by 3
Aoyama, K., Nakajima, Y., Meguro, S., Sato, Y., Goto, R., Hida, M., Arimitsu, T., Kasuga, Y., Tanaka, M., & Itoh, H. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22504 · Cited by 4
“…hypoglycemia is defined using the definition for Level 2 and/or 3 of the American Diabetes Association (ADA) guidelines as follows: glucose 54 mg/dL (3.0 mmol/L) and/or a severe event characterized by altered mental and/or physical status requiring assistance for treatment of hypoglycemia [22].”
MethodInfluentialMamari, R., & Ibrahim, R. (2023) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2023.00831 · Cited by 2
Alkhaddo, J. B., Rung, J. M., Khowaja, A. A., Yin, Y., Richards, S. B., Drury-Gworek, C., Afreen, S., Rossi, C., & Manzi, S. (2024) · BMC Health Services Research · doi:10.1186/s12913-024-10745-2 · Cited by 3
“Therefore, the “low perform-ing” PCPs in this study who manage patients with high CCI indexes might in fact be appropriately pursuing less stringent A1c targets in accordance with guidelines [29].”
BackgroundAnil, D., Doddaiah, S. K., Shivaswamy, R. P., Gopi, A., Basheer, S., Yadav, D., Prakash, H., & Murthy, M. N. (2024) · BMJ Public Health · doi:10.1136/bmjph-2023-000717 · Cited by 3
A comprehensive review of the relationship between air pollution and type 2 diabetes
Dehghani, S., Oskoei, V., Yazdi, N. B., Yousefabad, S. S., Jafarian, A., Ghalhari, M. R., & Abolli, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-16080-6.00010-0 · Cited by 4
Ortiz-Zúñiga, Á., Amigó, J., Sánchez, M. D. F. G., Abad, M., Simó, R., Hernández, C., & Simó‐Servat, O. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111786 · Cited by 2
Kassahun, H., Genetu, A., Abuhay, T., & Tesfa, H. (2024) · BMJ Public Health · doi:10.1136/bmjph-2023-000828 · Cited by 2
“To safeguard patients from the consequences of diabetes and possibly preventable glycaemic burden, healthcare practitioners should emphasise on the significance of maintaining appropriate glycaemic control.”
Hypoglycemia in Critically Ill Patients
Ma, T., & Chen, L. L. (2024) · Critical Care Nursing Quarterly · doi:10.1097/cnq.0000000000000525 · Cited by 2
Prevalence of Chronic Disease and Cost Effectiveness of a Free Clinic
Dion, A. E., Roake, J., Mayeda, K., Elich, N. A., Parro, D., Nuckols, T., Tseng, M., & Phelan, S. (2024) · Journal of Community Health · doi:10.1007/s10900-024-01417-7 · Cited by 4
Short bouts of hypoxia improve insulin sensitivity in adults with type 2 diabetes
Zhao, J., Massoudian, S. D., Stray-Gundersen, S. O., Wojan, F., & Lalande, S. (2025) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00932.2024 · Cited by 2
Показники контролю рівня глікемії: сучасний стан питання
Kondratyshyn, A. R., Fik, M. S., Наумова, У. О., & Naumova, L. V. (2022) · Endokrynologia · doi:10.31793/1680-1466.2022.27-2.147 · Cited by 2
Atherosclerosis Risk Factors in Patients with Reactive Hypoglycemia
Landowska, M., Żebrowska, A., Fajer, K., Adamek, P., Kruk, A., Kałuża, B., & Franek, E. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s371706 · Cited by 3
Selenoprotein P levels in patients with diabetes mellitus with complications
İlanbey, B., Yücel, H. E., Uçar, C., & Kocamış, Ö. (2021) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-021-01029-0 · Cited by 3
Fasina, I., Agyei, O., Kim, J., Montgomery, E., Powers, S., & Plyler, D. (2021) · INNOVATIONS in pharmacy · doi:10.24926/iip.v12i4.3997 · Cited by 1
Snoek, F. J., Spaepen, E., Mojdami, D., Mönnig, E., Syring, K. E., Yan, Y., & Mitchell, B. D. (2022) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2022.100295 · Cited by 2
Diabetes mellitus: what the neurologists need to know
Stephens, J. W., Williams, D. M., & Chudleigh, R. A. (2022) · Practical Neurology · doi:10.1136/pn-2022-003395 · Cited by 2
Ramalho, D., Silva, M. L., Almeida, C., Rocha, L., Rocha, G., & Veríssimo, R. (2023) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2022.10.004 · Cited by 2
Oxidative status and its relationship with glycemic state in children with type 1 diabetes mellitus
Elshalkami, N. M. M. E.-D., Salem, N. A., Elshabrawy, W. O., & Abou-Elhassan, S. M. (2022) · Alexandria Journal of Pediatrics · doi:10.4103/ajop.ajop_39_22 · Cited by 4
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-12-04
- Volume
- 44
- Issue
- Supplement_1
- Pages
- S73-S84
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4236126199
- Cited by
- 847
- References
- 118
- Citations by year
- 2026: 43 · 2025: 80 · 2024: 115 · 2023: 156 · 2022: 265 · 2021: 187 · 2020: 1
- FWCI
- 23.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic targets, diabetes management, clinical guidelines, quality of care, level of evidence, treatment goals
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.